Table 5.

ICI-Associated MACE Univariable Analysis of Clinical Risk Factors with Noncardiovascular Death as a Competing Event

Major Adverse Cardiovascular Events
Immune Checkpoint Inhibitors	Hazard Ratio∗	95% Confidence Interval	p Value
ICI	1.18	0.57–2.43	0.66
ICI + prior ischemic heart disease	2.08	0.91–4.73	0.08
ICI + prior heart failure	0.73	0.10–5.39	0.76
ICI + SCLC diagnosis	0.58	0.08–4.36	0.60
ICI + thoracic radiotherapy	0.32	0.10–1.06	0.06
ICI + VEGFI or TKI	2.15	1.05–4.37	0.04
ICI + BNP elevation	2.73	1.33–5.60	0.01
ICI + troponin elevation	5.20	2.59–10.47	<0.001

SCLC = small-cell lung cancer; TKI = tyrosine kinase inhibitor; VEGFI = vascular endothelial growth factor inhibitor; other abbreviations as in Table 2.

^∗Hazard ratios presented in comparison with patients on non-ICI therapies and without concurrent risk factors.